Andrew Baum is a former surgeon who has leveraged his deep clinical and scientific expertise to become a visionary leader in the financial services industry and biopharmaceutical sector. He has more than 30 years of experience and a proven track record in leading high-impact research projects and teams, developing robust strategies, and forging global partnerships that have expanded markets and increased investor returns.

His most recent role was the Global Head of Healthcare Research for Citi Research, where he joined in 2011. Prior to this, he covered European Pharmaceuticals at Morgan Stanley for 14 years. He also worked as a U.K. Pharmaceuticals and Biotechnology analyst at Salomon Brothers. From 1994 to 1996, Andrew was a practicing physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford where he completed his residency.

Andrew has been recognized as the top ranked European Pharmaceutical Analyst six times in theDeveloped Europe & Emerging EMEA Research Survey, which allows management firms to provide views on the advice they receive from research analysts. His team of analysts consistently ranked in the top three teams in external EU and global investor polls (Institutional Investor, Greenwich, and Reuters). He has been widely sought after to share his insights with the most senior levels of management within the healthcare industry. He has regularly lectured for a number of prestigious organizations including IO360, The British Institute of Comparative Law, the World Vaccine Congress as well as occasional presentations to some of the leading management consultancies.

Andrew holds an M.A. degree in Physiological Sciences and a BM ChB degree from Oxford University and is a Fellow of the Royal Society of Medicine.